DIA-H09 – Anti-IDH1 R132H (Hu) aus Maus (Klon: H09) – 500 µl

Art.-Nr.
DIA-H09

Spezifität
IDH1 R132H
Spezies-Reaktivität
Human
Wirtsspezies
Maus
Isotyp
IgG2a
Klon
H09
Klonalität (Mono-/Polyklonal)
monoklonal
Anwendung
Immunhistochemie (Paraffingewebe)
Western Blot
Immunhistochemie (IHC)
Verdünnung
Histo-/Zytochemie 1:20
Format
Lyophilisat
gereinigter Antikörper (aus Kulturüberstand)
Produktlinie / Thema
Tumormarker/-biologie
Neurobiologie
Zweckbestimmung
für In-vitro-Diagnostik
Temperatur – Lagerung
2-8°C
Suchcode
DIAH09
IHC, FFPE, Paraffin
Hersteller / Marke
dianova

Der anti-IDH1 R132H Antikörper Klon H09 (unter exklusiver Lizenz für dianova vom Deutschen Krebsforschungszentrum, DKFZ) ist in verschiedenen CE IVD registrierten Formaten erhältich:

Kat.Nr.ProduktFormStatusMengePreis
DIA-H09anti-IDH1 R132H, Klon H09konzentriert, lyophilisiertCE IVD500 µl482,00 €
DIA-H09-Manti-IDH1 R132H, Klon H09konzentriert, lyophilisiertCE IVD100 µl142.00 €
MAD-000475QD-3anti-IDH1 R132H, Klon H09vorverdünnt, gebrauchsfertigCE IVD3 ml264,00 €
MAD-000475QD-7anti-IDH1 R132H, Klon H09vorverdünnt, gebrauchsfertigCE IVD7 ml482,00 €
MAD-000475QD-12anti-IDH1 R132H, Klon H09vorverdünnt, gebrauchsfertigCE IVD12 ml826,00 €
  • DIA-H09 wird als konzentrierter Antikörper von dianova produziert und kann flexibel, mit unterschiedlichen Verdünnungen, für verschiedene Färbeprotokollen optimal adaptiert werden.
  • MAD-000745QD wird für dianova von Master Diagnóstica als gebrauchsfertige Antikörper-Lösung hergestellt.
Immunohistochemistry of human IDH1 R132H in formalin-fixed paraffin-embedded brain tissue sections

Strong reaction of IDH1 mutation specific antibody clone H09 in tumor center of anaplastic oligoastrocytoma.

A

Infiltration zone of anaplastic astrocytoma with specific labelling of infiltrating glioma cells by antibody clone H09.

B

Identification of single tumor cells in white matter distant from tumor center with IDH1 mutation specific antibody clone H09.

C

Immunohistochemical staining (IHC) with anti-IDH1 R132H Antibody (clone H09) - dianova

D

Immunohistochemical staining (IHC) with anti-IDH1 R132H Antibody (clone H09) - dianova

E

Immunohistochemical staining (IHC) with anti-IDH1 R132H Antibody (clone H09) - dianova

F

A: Strong reaction of IDH1 mutation specific antibody clone H09 in tumor center of anaplastic oligoastrocytoma.
B: Infiltration zone of anaplastic astrocytoma with specific labelling of infiltrating glioma cells by antibody clone H09.
C: Identification of single tumor cells in white matter distant from tumor center with antibody clone H09.
D: Cortex infiltrated by oligodendroglioma with specific labelling of tumor cells by antibody clone H09.
E: Double staining of GFAP (glial fibrillary acidic protein, red) and clone H09 (brown) of oligodendroglioma infiltration zone demonstrating specific labelling of tumor cells but not of GFAP positive reactive astrocytes.
F: Strong reaction of antibody clone H09 with IDH1 R132H mutated diffuse astrocytoma (left) but not with wild type tumor (right).

(pictures courtesy of Prof. Dr. med. Andreas von Deimling, Department of Neuropathology, University Heidelberg/
Clinical Co-operation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany)

Background

Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.

Combined immunohistochemistry of ATRX (dianova clone AX1) and IDH1R132H (dianova clone H09)
substitutes molecular testing.

The routine practical approach for diagnosing astrocytomas and oligodendrogliomas begins with perfoming IHC for IDH1 R132H and ATRX expression. Stepwise analysis of molecular parameters with initial IHC for ATRX and IDH1 R132H followed by 1p/19q analysis and then by IDH sequencing significantly reduces the number of molecular tests required for unequivocal diagnosis (Reuss et al., 2015). Learn more…

References
  1. Capper D et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118(5): 599-601, 2009
  2. Capper D et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20(1): 245-254, 2010
  3. Preusser M et al. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clinical Neuropathology, 30(5):217-230, 2011
  4. Van den Bent MJ et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173–178, 2013
  5. Schumacher T et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, DOI:10.1038/nature13387
  6. Reuss DE et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an „integrated“ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 129(1):133-146, 2015
  7. David NL et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol., 131:803-820, 2016